Trial Condition(s):
Therapeutic Equivalency, Postmenopause, Hormone Replacement Therapy
Study to demonstrate bioequivalence after single oral administration of the two different Estradiol Valerate-containing preparations in postmenopausal women
Bayer Identifier:
91121
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
36
Trial Dates
Phase
1
Could I receive a placebo?
No
Products
Estradiol Valerate (EV, DS00124)
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
| Locations |
|---|
Trial Design
Open-label, randomized, two-way crossover study to demonstrate bioequivalence after single oral administration of the two different estradiol valerate-containing preparations Estradiol 2 mg Jenapharm and Merimono 2 mg in 36 healthy postmenopausal women
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
